Log in to your Inderes Free account to see all free content on this page.
Cantargia
3.986 SEK +1.32%1,314 investors are following this company
Cantargia is a pharmaceutical company. Today, there is specialization in the development of antibody drugs used in the treatment of leukemia and other cancers such as lung and pancreatic cancer. The company's objective is to develop, sell and license drug candidates to companies operating in the mentioned work area. The largest operations are in the Nordic market, with headquarters in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
CANTA
Daily low / high price
3.902 / 3.998
SEK
Market cap
732.18M SEK
Turnover
425.43K SEK
Volume
107K
Latest videos
Financial calendar
Interim report
15.11.2024
Annual report
21.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Fjärde AP-fonden | 9.9 % | 9.9 % |
Första AP-Fonden | 7.1 % | 7.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
![Cantargia, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/19f89e3f-8a70-4277-89ae-19e9429fec95.png)
Cantargia, Audiocast with teleconference, Q2'24
Correction: Cantargia publishes half-year report 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Cantargia publishes half-year report 2024
Cantargia reports presentation of new preclinical data supporting CAN10 in fibrotic lung diseases
Cantargia reports timelines for nadunolimab clinical trials in leukemia and triple negative breast cancer
Cantargia presents the interim report for Q2 2024 on August 28 at 3.00 p.m.
Cantargia reports progress and strong biomarker data from phase I clinical trial with CAN10
Cantargia reports organisational change
Cantargia presents Phase 2 clinical data in pancreatic cancer with nadunolimab at ESMO Gastrointestinal Cancer Congress 2024
Cantargia reports further progress in ongoing phase 1 clinical trial with CAN10
Cantargia strengthen management team with the appointment of Ton Berkien as Chief Business Officer
Cantargia ASCO presentation highlights positive clinical data on nadunolimab counteracting neuropathy
Cantargia presents new positive clinical data on nadunolimab counteracting chemotherapy induced neuropathy
Annual General Meeting in Cantargia AB (publ)
Redeye: Cantargia Q1 2024 - Notable Cost Reductions
![Cantargia, Audiocast with teleconference, Q1'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/0db88371-628c-4bb6-adbe-7a9995b4204f.png)